Evidence map›Paper›PMID 36790811›Full record

ArticleJAMA network open2023

Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.

Jessica Briggs, Saki Takahashi, Patience Nayebare, Gloria Cuu, John Rek, Maato Zedi, Timothy Kizza, Emmanuel Arinaitwe, Joaniter I Nankabirwa, Moses Kamya and 7 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Jessica BriggsDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Saki TakahashiDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Patience NayebareInfectious Diseases Research Collaboration, Kampala, Uganda.
Gloria CuuInfectious Diseases Research Collaboration, Kampala, Uganda.
John RekInfectious Diseases Research Collaboration, Kampala, Uganda.
Maato ZediInfectious Diseases Research Collaboration, Kampala, Uganda.
Timothy KizzaInfectious Diseases Research Collaboration, Kampala, Uganda.
Emmanuel ArinaitweInfectious Diseases Research Collaboration, Kampala, Uganda.
Joaniter I NankabirwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Moses KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Prasanna JagannathanDepartment of Medicine, Stanford University, Stanford, California.
Karen JacobsonDepartment of Medicine, Stanford University, Stanford, California.
Philip J RosenthalDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Grant DorseyDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Bryan GreenhouseDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Isaac SsewanyanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Isabel Rodríguez-BarraquerDivision of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco.
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USStanford University · USMakerere University · UG

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Uncovering the dynamics of human pathogens using high throughput multiplexed serological toolsR35GM138361 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RODRÍGUEZ-BARRAQUER, ISABEL · 2020 to 2024
$1.6M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Improving the accuracy of malaria surveillance with serology and parasite genetic dataK23AI166009 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jessica Briggs · 2022 to 2026
$955k
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS K43 TW010365NIAID NIH HHS K23 AI166009NIAID NIH HHS K24 AI144048NIAID NIH HHS U19 AI089674NIGMS NIH HHS R35 GM138361
6 · The paper itself

Abstract

Importance: Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa owing to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level. Objective: To estimate SARS-CoV-2 seroprevalence, attack rates, and reinfection in eastern Uganda using serologic surveillance from 2020 to early 2022. Design, Setting, and Participants: This cohort study was conducted in the Tororo and Busia districts of eastern Uganda. Plasma samples from participants in the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda Border Cohort were obtained at 4 sampling intervals: October to November 2020, March to April 2021, August to September 2021, and February to March 2022. Each participant contributed up to 4 time points for SARS-CoV-2 serology, with almost half of all participants contributing at all 4 time points, and almost 90% contributing at 3 or 4 time points. Information on SARS-CoV-2 vaccination status was collected from participants, with the earliest reported vaccinations in the cohort occurring in May 2021. Main Outcomes and Measures: The main outcomes of this study were antibody responses to the SARS-CoV-2 spike protein as measured with a bead-based serologic assay. Individual-level outcomes were aggregated to population-level SARS-CoV-2 seroprevalence, attack rates, and boosting rates. Estimates were weighted by the local age distribution according to census data. Results: A total of 1483 samples from 441 participants living in 76 households were tested. Of the 441 participants, 245 (55.6%) were female, and their mean (SD) age was 16.04 (16.04) years. By the end of the Delta wave and before widespread vaccination, adjusted SARS-CoV-2 seroprevalence was 67.7% (95% credible interval [CrI], 62.5%-72.6%) in the study population. During the subsequent Omicron wave, 84.8% (95% CrI, 67.9%-93.7%) of unvaccinated, previously seronegative individuals were infected for the first time, and 50.8% (95% CrI, 40.6%-59.7%) of unvaccinated, already seropositive individuals were likely reinfected, leading to an overall seropositivity of 96.0% (95% CrI, 93.4%-97.9%) in this population. These results suggest a lower probability of reinfection in individuals with higher preexisting antibody levels. There was evidence of household clustering of SARS-CoV-2 seroconversion. No significant associations were found between SARS-CoV-2 seroconversion and gender, household size, or recent Plasmodium falciparum malaria exposure. Conclusions and Relevance: In this cohort study in a rural population in eastern Uganda, there was evidence of very high SARS-CoV-2 infection rates throughout the pandemic inconsistent with national level case data and high reinfection rates during the Omicron wave.

Indexed as

COVID-19SARS-CoV-2AdolescentCohort StudiesCOVID-19 VaccinesFemaleHumansMaleReinfectionRural PopulationSeroepidemiologic StudiesSpike Glycoprotein, CoronavirusUgandaCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID36790811
PMCPMC9932849
OpenAlexW4320856906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.